Truist Financial’s Zymeworks ZYME Stock Holding History

Truist Financial’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25,500	Closed	-$418K	–	2876
2021 Q4	$418K	Sell	25,500 -500	-2%	-$10.4K	﹤0.01%	2128
2021 Q3	$755K	Buy	+26,000	New	+$864K	﹤0.01%	1770

Other funds holding ZYME

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Truist Financial's ZYME Position: Q1 2022 in Review

Truist Financial sold out of Zymeworks (ZYME) in Q1 2022, closing a stake of 25,500 shares — an estimated $418K sold.

Truist Financial first reported a position in ZYME in Q3 2021 and held it in 2 quarters. The position peaked at $755K in Q3 2021. 120 funds tracked by Wall St. Rank hold ZYME as of Q1 2022.

Truist Financial reported no remaining Zymeworks position as of Q1 2022 after selling out during the quarter.
Truist Financial sold 25,500 Zymeworks shares in Q1 2022, an estimated $418K.
Truist Financial first reported a position in Zymeworks in Q3 2021 and held it in 2 quarters.
Truist Financial's Zymeworks position peaked at $755K in Q3 2021.
120 funds tracked by Wall St. Rank held Zymeworks as of Q1 2022.

Based on Truist Financial's 13F filing for Q1 2022, filed 22 Apr 2022.